Cabergoline Reduces OHSS

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The present study was designed to provide clinical confirmation of Cb2's value as a new approach in the prevention of increased vascular permeability and hemoconcentration, both signs of OHSS in humans, and in order to explore its mechanism of action. To this end, a prospective, randomized, placebo-controlled study was designed in which Cb2 was employed in women at risk of OHSS after gonadotropin administration for ART. Simultaneously, ovarian perfusion was assessed in these patients using MR pharmacokinetic modeling.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
• Treatments: Cabergoline; Dopamine; Dopamine Agonists

Criteria

Inclusion Criteria:

• 18 - 35 years old healthy women, with risk of developing OHSS.

Exclusion Criteria:

• No risk of developing OHSS; < 20 oocytes retrieved.